Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Gentamicin sulfate
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Gentamicin 0.3% ear/eye drops
1103010G0AAAFAF
|
Gentamicin sulfate (Ear/Eye) | Gentamicin sulfate | Eye | 10,313 |
|
Gentamicin 80mg/2ml solution for injection ampoules
0501040H0AAAAAA
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | 697 |
|
Gentamicin 80mg/2ml solution for injection vials
0501040H0AAAMAM
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | 147 |
|
Cidomycin 80mg/2ml solution for injection ampoules
0501040H0BBAAAA
|
Cidomycin (Systemic) | Gentamicin sulfate | Infections | 68 |
|
Gentamicin 20mg/2ml solution for injection vials
0501040H0AAAEAE
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | 10 |
|
Cidomycin Adult Injectable 80mg/2ml inj vials
0501040H0BBAFAM
|
Cidomycin (Systemic) | Gentamicin sulfate | Infections | 8 |
|
Gentamicin 0.1% cream
1310012I0AAAEAE
|
Gentamicin sulfate (Topical) | Gentamicin sulfate | Skin | 8 |
|
Gentamicin 20mg/2ml solution for injection ampoules
0501040H0AABBBB
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | 4 |
|
Gentamicin 1.5% eye drops preservative free
1103010G0AAAKAK
|
Gentamicin sulfate (Ear/Eye) | Gentamicin sulfate | Eye | 2 |
|
Genticin 0.3% eye/ear drops
1103010G0BDAAAF
|
Genticin (Ear/Eye) | Gentamicin sulfate | Eye | 1 |
|
Cidomycin Intrathecal 5mg/1ml inj ampoules
0501040H0BBADAH
|
Cidomycin (Systemic) | Gentamicin sulfate | Infections | No data available |
|
Cidomycin Paediatric 20mg/2ml solution for injection vials
0501040H0BBACAE
|
Cidomycin (Systemic) | Gentamicin sulfate | Infections | No data available |
|
Garamycin 0.3% eye/ear drops
1103010G0BCAAAF
|
Garamycin (Ear/Eye) | Gentamicin sulfate | Eye | No data available |
|
Gentamicin 0.3% eye drops 0.5ml unit dose preservative free
1103010G0AAAAAA
|
Gentamicin sulfate (Ear/Eye) | Gentamicin sulfate | Eye | No data available |
|
Gentamicin 1.5% eye drops
1103010G0AAAHAH
|
Gentamicin sulfate (Ear/Eye) | Gentamicin sulfate | Eye | No data available |
|
Gentamicin 1.9% eye drops preservative free
1103010G0AAAMAM
|
Gentamicin sulfate (Ear/Eye) | Gentamicin sulfate | Eye | No data available |
|
Gentamicin 240mg/80ml infusion bags
0501040H0AABDBD
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | No data available |
|
Gentamicin 30mg/5ml oral suspension
0501040H0AAAZAZ
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | No data available |
|
Gentamicin 35mg/5ml oral suspension
0501040H0AABABA
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | No data available |
|
Gentamicin 360mg/120ml infusion bags
0501040H0AABEBE
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | No data available |
|
Gentamicin 40mg/1ml solution for injection ampoules
0501040H0AAAQAQ
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | No data available |
|
Gentamicin 45mg/5ml oral solution
0501040H0AABFBF
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | No data available |
|
Gentamicin 50mg/5ml oral solution
0501040H0AAAWAW
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | No data available |
|
Gentamicin 5mg/1ml solution for injection ampoules
0501040H0AAAHAH
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | No data available |
|
Gentamicin 62.5mg/5ml oral solution
0501040H0AAAXAX
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.